ERBB2 and cancer: HER2-targeted therapies (trastuzumab, pertuzumab, TDM1, and lapatinib) are efficient at attenuating primary tumor progression and cancer relapse, but on the other hand, they apply a high selection pressure on the tumor to favor the clones with mutations in Her2 that become resistant to the therapy.